THOUGHTS &
NOTES

These are the copies of my LINKEDIN posts in the aftermath of multiple trial patient death from China IIT reported in 2026. Part I is a summary of the public reporting and my analysis is included in Part II-V: China IIT - PART II Since my last post, very sadly, a third patient death from China IIT has been reported. RIBOX with their LNP-delivered circular RNA therapy had a death in their IIT, even though US FDA has just recently cleared their IND application (which RIBOX ap

In my previous article, I discussed how the conflict between rapid development ("China Speed") and inconsistent quality standards...